{"nctId":"NCT00513292","briefTitle":"Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery","startDateStruct":{"date":"2007-07"},"conditions":["HER2/Neu Positive","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer"],"count":280,"armGroups":[{"label":"FEC-75 then Paclitaxel/trastuzumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Epirubicin Hydrochloride","Other: Laboratory Biomarker Analysis","Drug: Paclitaxel","Procedure: Therapeutic Conventional Surgery","Biological: Trastuzumab"]},{"label":"Paclitaxel/trastuzumab then trastuzumab/FEC-75","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Drug: Epirubicin Hydrochloride","Other: Laboratory Biomarker Analysis","Drug: Paclitaxel","Procedure: Therapeutic Conventional Surgery","Biological: Trastuzumab"]}],"interventions":[{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Epirubicin Hydrochloride","otherNames":["Ellence","IMI-28","Pharmorubicin PFS"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"]},{"name":"Therapeutic Conventional Surgery","otherNames":[]},{"name":"Trastuzumab","otherNames":["ABP 980","Anti-c-ERB-2","Anti-c-erbB2 Monoclonal Antibody","Anti-ERB-2","Anti-erbB-2","Anti-erbB2 Monoclonal Antibody","Anti-HER2/c-erbB2 Monoclonal Antibody","Anti-p185-HER2","c-erb-2 Monoclonal Antibody","HER2 Monoclonal Antibody","Herceptin","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","MoAb HER2","Monoclonal Antibody c-erb-2","Monoclonal Antibody HER2","PF-05280014","rhuMAb HER2","Trastuzumab Biosimilar ABP 980","Trastuzumab Biosimilar PF-05280014"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of invasive adenocarcinoma by core needle biopsy\n\n  * Fine needle aspiration allowed provided primary tumor size \\< 2 cm and lymph node metastases are present\n  * Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present\n* Primary tumor ≥ 2 cm and/or ≥ 1 biopsy-positive lymph node\n* HER2-positive disease\n\n  * Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification\n  * Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score\n* Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed\n\n  * Synchronous invasive breast cancer not allowed\n* Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed\n\n  * Those treated with radiation therapy are not allowed\n* No definitive clinical or radiologic evidence of metastatic disease\n* No history of invasive breast cancer\n* Hormone receptor status known\n* Menopausal status not specified\n* ECOG performance status of 0 -1\n* Absolute neutrophil count ≥ 1,200/mm³\n* Platelet count ≥ 100,000/mm³\n* Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal \\[ULN\\]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin\n* Alkaline phosphatase ≤ 2.5 times ULN\n* AST ≤ 1.5 times ULN\n* Creatinine normal\n* Left ventricular ejection fraction (LVEF) ≥ 55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months\n* Patients with either skeletal pain or alkaline phosphatase that is \\> ULN but ≤ 2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease\n\n  * Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy\n* Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence\n\n  * Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:\n\n    * Carcinoma in situ of the cervix\n    * Colon carcinoma in situ\n    * Melanoma in situ\n    * Basal cell and squamous cell carcinoma of the skin\n* No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin®) including any of the following:\n\n  * Active cardiac disease\n  * Angina pectoris that requires the use of antianginal medication\n  * Cardiac arrhythmia requiring medication\n  * Severe conduction abnormality\n  * Clinically significant valvular disease\n  * Cardiomegaly on chest x-ray\n  * Ventricular hypertrophy on EKG\n  * Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)\n\n    * Patients with hypertension that is well controlled on medication are eligible\n  * History of cardiac disease\n  * Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests\n  * Documented congestive heart failure\n  * Documented cardiomyopathy\n* No sensory or motor neuropathy ≥ grade 2, as defined by the NCI's CTCAE v3.0\n* Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy\n* Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration\n* Not pregnant or nursing\n* No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements\n* No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens\n* No prior surgical axillary staging procedure\n\n  * Prior non-excisional biopsy of an axillary node allowed\n* No prior treatment for this breast cancer\n\n  * Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry\n  * Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery\n* No prior therapy with anthracyclines or taxanes for any malignancy\n* No other investigational agents within the past 30 days\n* No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)\n* No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy","description":"Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Combined pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy","description":"pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Asymptomatic Decreases From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 12","description":"The summary of asymptomatic decrease in LVEF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Asymptomatic Decreases From Baseline in LVEF at Week 24","description":"The summary of asymptomatic changed in LVEF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"73.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"LVEFs From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans as Reported at 12 Week","description":"All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks \\[median change from baseline Inter Quartile Range (IQR)\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"-3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in LVEFs (From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans) From Baseline and at 24 Week","description":"Difference from pretreatment LVEF (%) at 24 weeks \\[median change from baseline Inter Quartile Range (IQR)\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":null},{"groupId":"OG001","value":"-4","spread":null}]}]}]},{"type":"SECONDARY","title":"Breast Conservation","description":"Surgery was categorized as breast conserving surgery (\"Partial Mastectomy\") or non-conserving surgery (\"Total Mastectomy\" or \"Modified Radical Mastectomy). Reported below is the percentage of patients receiving \"Partial Mastectomy\". This was calculated by dividing the number of patients receiving \"Partial Mastectomy\" by the total number of patients undergoing surgery multiplied by 100 (to obtain the percentage).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"39.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (DFS)","description":"DFS defined as inoperable progressive disease, gross residual disease following definitive surgery, local, regional or distant recurrence, contralateral breast cancer, other second primary cancers, and death prior to recurrence or second primary cancer. DFS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":138},"commonTop":["Fatigue","Nausea","Peripheral sensory neuropathy","Alopecia","Diarrhea"]}}}